http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Cho, Sung Hwan,Jo, Seong Soon,Hwang, Ihn,Sung, Jinwoo,Seo, Jungmok,Jung, Seok-Heon,Bae, Insung,Choi, Jae Ryung,Cho, Himchan,Lee, Taeyoon,Lee, Jin Kyun,Lee, Tae-Woo,Park, Cheolmin American Chemical Society 2013 ACS NANO Vol.7 No.12
<P>Electroluminescent (EL) devices operating at alternating current (AC) electricity have been of great interest due to not only their unique light emitting mechanism of carrier generation and recombination but also their great potential for applications in displays, sensors, and lighting. Despite great success of AC–EL devices, most device properties are far from real implementation. In particular, the current state-of-the art brightness of the solution-processed AC–EL devices is a few hundred candela per square meter (cd m<SUP>–2</SUP>) and most of the works have been devoted to red and white emission. In this manuscript, we report extremely bright full color polymer AC–EL devices with brightness of approximately 2300, 6000, and 5000 cd m<SUP>–2</SUP> for blue (B), green (G), and red (R) emission, respectively. The high brightness of blue emission was attributed to individually networked multiwalled carbon nanotubes (MWNTs) for the facile carrier injection as well as self-assembled block copolymer micelles for suppression of interchain nonradiative energy quenching. In addition, effective FRET from a solution-blended thin film of B-G and B-G-R fluorescent polymers led to very bright green and red EL under AC voltage, respectively. The solution-processed AC–EL device also worked properly with vacuum-free Ag paste on a mechanically flexible polymer substrate. Finally, we successfully demonstrated the long-term operation reliability of our AC–EL device for over 15 h.</P><P><B>Graphic Abstract</B> <IMG SRC='http://pubs.acs.org/appl/literatum/publisher/achs/journals/content/ancac3/2013/ancac3.2013.7.issue-12/nn4040926/production/images/medium/nn-2013-040926_0006.gif'></P><P><A href='http://pubs.acs.org/doi/suppl/10.1021/nn4040926'>ACS Electronic Supporting Info</A></P>
( Jong Kil Park ),( Ihn Cheol Seong ),( Baek Jo Kim ),( Woo Sik Jung ),( Ri Yu Lu ) 한국환경과학회 2014 한국환경과학회지 Vol.23 No.1
In the present study, we analyzed precipitation patterns and diurnal variation trends of hourly precipitation intensity due to climate change. To that end, we used the hourly precipitation data obtained from 26 weather stations around South Korea, especially Busan, from 1970 to 2009. The results showed that the hourly precipitation was concentrated on a specific time of day. In particular, the results showed the so-called "morning shift" phenomenon, which is an increase in the frequency and intensity of hourly precipitation during the morning. The morning shift phenomenon was even more pronounced when a higher level of hourly precipitation intensity occurred throughout the day. Furthermore, in many regions of Korea, including Busan, this morning shift phenomenon became more prevalent as climate change progressed.
( So Yeon Lee ),( Yoon Seok Choi ),( Bhum-suk Keam ),( Keon-uk Park ),( Ki-hyeong Lee ),( Ihn-seong Jo ),( Eun-kee Song ),( Sang-gon Park ),( Ik-chan Song ),( Hyo Jin Lee ),( Deog Yeon Jo ),( Samyong 대한내과학회 2016 대한내과학회 추계학술대회 Vol.2016 No.1
Introduction: Standard treatment for locally advanced (stage III-IV) head and neck squamous cell cancer (LA-HNSCC) is concurrent chemoradiation therapy (CCRT) with cisplatin 100mg/m2 every three weeks. For medically unfit patients susceptible to treatment-related adverse events, low-dose weekly cisplatin can be used as an alternative. In previous studies, weekly cisplatin-based regimen showed fair efficacy and tolerable toxicity profiles. In this study, we retrospectively compared the therapeutic outcomes of low-dose weekly cisplatin regimen and standard regimen in CCRT for LA-HNSCC.?Methods: The medical records of histologically confirmed LA-HNSCC patients were retrospectively reviewed from Jan 1, 2007 to Dec 31, 2012. 224 patients who were treated with CCRT as initial treatment were enrolled. Among them, 155 patients were treated with low-dose (30 mg/m2) weekly cisplatin and 69 patients were treated with standard-dose (100 mg/m2) three-weekly. Dose intensity of cisplatin in each group was calculated as proportion of delivered dose in full regimen dosage.?Results: Baseline characteristics of both groups did not differ significantly, except that standard-dose group contained more larynx cancer patients. Although dose intensity of standard-dose cisplatin group (84%) were lower than low-dose weekly cisplatin group (91%), difference in median progression free survival (31.2 month vs 26.3 month; p=0.469) and overall survival (36.6 month vs 31.6 month; p=0.439) was not statistically significant between standard-dose group and low-dose group.?Conclusions: In the present study, low-dose weekly cisplatin was not inferior to standard-dose cisplatin in terms of survival outcomes. Prospective comparison of standard-dose three-weekly and low-dose weekly cisplatin is warranted.
증례 : 신장 ; 혈우병이 동반된 당뇨병성 만성 신부전 환자에서 복막투석 경험 1예
최현주 ( Hyun Ju Choi ),김민옥 ( Min Ok Kim ),최소연 ( So Yeon Choi ),김영근 ( Young Keun Kim ),박상현 ( Sang Hyun Park ),조인성 ( Ihn Seong Jo ) 대한내과학회 2009 대한내과학회지 Vol.76 No.1
혈우병은 혈액 응고인자의 결핍으로 출혈경향을 갖는 선천성 유전질환이다. 혈우병 환자가 만성 신부전으로 진행하는 경우는 드물게 발생하며, 신대체요법을 필요로 하는 경우 실제적인 치료지침은 없는 실정이다. 저자들은 혈우병 환자에게서 합병증 없이 복막투석 도관삽입시술 후 복막투석을 시행하고 유지한 예를 경험하였기에 보고하는 바이다. Long-term dialysis is undertaken infrequently in patients with hemophilia and chronic renal failure, and there are no definite guidelines for the treatment of end-stage renal disease in hemophiliacs. We report a case of peritoneal dialysis in a hemophiliac with diabetic chronic renal failure. A 46-year-old man with severe hemophilia was admitted to our hospital for decreased visual acuity and the management of uremia. After vitrectomy, he was started on hemodialysis to treat his uremic bleeding diathesis. To avoid bleeding through a vascular access site, peritoneal dialysis therapy for long-term treatment was proposed. A surgical peritoneal catheter was introduced with simultaneous factor VIII administration. In the seven subsequent months, no episodes of intraperitoneal or retroperitoneal hemorrhage have been observed. Continuous ambulatory peritoneal dialysis may be a relatively safe dialysis modality without danger of bleeding in hemophiliacs. (Korean J Med 76:96-99, 2009)